Poster Abstracts

• PII-001 THE COMPLEXITY AND DYNAMICS OF TUMOR RESPONSE TO VORINOSTAT CAN BE ELUCIDATED BY INTEGRATING MULTIPLE LARGE HIGH-THROUGHPUT DATASETS.
• PII-002 <i>IN VITRO</i>-<i>IN VIVO</i> CORRELATION (IVIVC) OF DRUG INDUCED INHIBITION OF CREATININE TUBULAR SECRETION USING MDCK CELLS EXPRESSING OCT2/OAT2/OCT3/MATE1/MATE2K TRANSPORTERS.
• PII-003 ENDOGENOUS BILE ACIDS ARE POTENTIAL BIOMARKERS FOR OATP1B3 ACTIVITY.
• PII-004 GENOME WIDE ASSOCIATION ANALYSIS WITH AMINE METABOLITES REVEALS NOVEL LOCI IMPACTING HUMAN METABOLOMIC PROFILES.
• PII-005 EFFECTS OF CC-220, AN ORAL IMMUNOMODULATOR, ON IMMUNE RESPONSES.
• PII-006 INTERACTIVE GENOTYPE-BASED DOSING GUIDELINES.
• PII-007 PRECLINICAL EFFICACY OF T-LAK CELL-ORIGINATED PROTEIN KINASE INHIBITOR IN FLT3-ITD MUTANT ACUTE MYELOID LEUKEMIA.
• PII-008 PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODEL PREDICTIONS OF CYP MEDIATED DDIS: POTENTIAL INTERACTIONS BETWEEN ICA-105665 AND CYP ENZYME INDUCERS.
• PII-009 INTRA-ARTERIAL MICRODOSING (IAM), A NOVEL DRUG DEVELOPMENT APPROACH, PROOF OF CONCEPT IN RATS.
• PII-010 PHARMACOKINETIC INTERACTION BETWEEN ROSUVASTATIN AND FENOFIBRATE IN HEALTHY VOLUNTEERS.
• PII-011 EXPLORATORY HUMAN ABUSE POTENTIAL ASSESSMENT OF CENTANAFADINE, A NOVEL TRIPLE REUPTAKE INHIBITOR.
• PII-012 STATIN INHIBITION OF LACTIC ACID TRANSPORT IN HUMAN SKELETAL MUSCLE.
• PII-013 IDENTIFICATION AND FUNCTIONAL STUDIES OF CYP4V2 VARIANTS AMONG KOREAN POPULATION.
• PII-014 THE EFFECT OF INTRACELLULAR METHADONE ON HERG CURRENT IS MODULATED BY THE COEXPRESSION OF THE CYP450 ISOZYME 2B6.
• PII-015 ILOPERIDONE METABOLISM IN HUMAN HEART.
• PII-016 THE EFFECT OF CIGARETTE SMOKING ON THE PLASMA AND URINE EICOSANOID METABOLIC PROFILE IN A HEALTHY MALE POPULATION.
• PII-017 CYP2D6 GENE COPY NUMBER VARIATION (CNV): HOW ACCURATE IS THE AFFYMETRIX CytoScan HD?.
• PII-018 METABOLISM OF OLANZAPINE IN HUMAN HEART MICROSOMES.
• PII-019 PHARMACOGENOMICS OF MITHRAMYCIN-INDUCED HEPTATOTOXICITY.
• PII-020 RHEIN ELICITS <i>IN VITRO</i> CYTOTOXICITY IN PRIMARY HUMAN LIVER L-02 (HL-7702) CELLS BY INDUCING APOPTOSIS VIA MITOCHONDRIA-MEDIATED PATHWAY.
• PII-021 RIFAMPIN REGULATION OF DRUG TRANSPORTERS AND THE ROLE OF MICRORNA IN HUMAN HEPATOCYTES.
• PII-022 ABC TRANSPORTER POLYMORPHISMS ARE ASSOCIATED WITH IRINOTECAN EXPOSURE AND NEUTROPENIA.
• PII-023 INTERINDIVIDUAL VARIABILITY IN CYP2D6 ACTIVITY IN HUMAN LIVER MICROSOMES TO CHARACTERIZE RARE GENETIC VARIATION.
• PII-024 P-MAP: NETWORK BIOLOGY APPLIED TO DETERMINE CELLULAR SENSITIVITY OF DRUG RESPONSE IN TRIPLE NEGATIVE BREAST CANCER CELL LINES.
• PII-025 INTENSIVE STATINS EXHIBIT VARIABLE PARADOXICAL EFFECTS WHEN COMBINED WITH FIBRATES IN A MODEL OF CARDIOVASCULAR DISEASE.
• PII-026 GENOME-WIDE ASSOCIATION STUDY TO IDENTIFY SUSCEPTIBILITY LOCI ASSOCIATED WITH HEMORRHAGIC COMPLICATIONS AMONG AFRICAN AMERICAN PATIENTS ON STABLE WARFARIN DOSE.
• PII-027 ASSESSMENT OF THE POTENTIAL FOR DRUG-DRUG INTERACTIONS BETWEEN TRASTUZUMAB EMTANSINE (T-DM1) AND CYP3A INHIBITORS OR INDUCERS AND THE IMPACT ON ITS PK AND SAFETY.
• PII-028 POPULATION PHARMACOKINETIC (PPK) MODELING OF AXITINIB IN PATIENTS WITH METASTATIC OR UNRESECTABLE LOCALLY ADVANCED THYROID CANCER.
• PII-029 POPULATION PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSIS OF VORINOSTAT IN PATIENTS WITH ADVANCED SOLID TUMORS WITH VARYING DEGREES OF HEPATIC FUNCTION.
• PII-030 TARGETING TUMOR-ASSOCIATED HYPOXIA TO OVERCOME CHEMORESISTANCE IN PANCREATIC DUCTAL ADENOCARCINOMA (PDA).
• PII-031 A PHARMACOKINETIC AND PHARMACOGENETIC STUDY OF ALISERTIB COMBINED WITH IRINOTECAN AND TEMOZOLOMIDE IN CHILDREN AND ADOLESCENTS WITH RELAPSED OR REFRACTORY NEUROBLASTOMA.
• PII-032 A MODEL RELATING OVERALL SURVIVAL RELATED TO TUMOR GROWTH INHIBITION IN RENAL CELL CARCINOMA PATIENTS TREATED WITH SUNITINIB, AXITINIB OR TEMSIROLIMUS.
• PII-033 POPULATION PHARMACOKINETICS OF BEVACIZUMAB: ANALYSIS OF INDIVIDUAL DATA FROM 1,792 PATIENTS WITH SOLID TUMORS FROM 15 STUDIES.
• PII-034 EVOLOCUMAB PHARMACOKINETICS AND ITS EFFECTS ON LDL-C AND PCSK9 LOWERING IN SUBJECTS WITH MILD OR MODERATE HEPATIC IMPAIRMENT.
• PII-035 DIFFERENCES IN MYCOPHENOLIC ACID AND METABOLITE, MYCOPHENOLIC ACID GLUCURONIDE EXPOSURES BETWEEN CALCINEURIN INHIBITOR REGIMENS POST-RENAL TRANSPLANT.
• PII-036 ALTERED VITAMIN A HOMEOSTASIS IN CHRONIC KIDNEY DISEASE.
• PII-037 SEARCHING FOR OPTIMAL THERAPY OF THE AMYLOID PATHOLOGY USING MECHANISM-BASED MODEL.
• PII-038 GENOME-WIDE ASSOCIATION STUDY IDENTIFIES NOVEL SUSCEPTIBILITY LOCI FOR VENOUS THROMBOEMBOLISM IN AFRICAN AMERICANS.
• PII-039 A TWO-WEEK COURSE OF HIGH-DOSE INTEGRASE INHIBITORS DOES NOT LEAD TO NEPHROTOXICITY IN MICE.
• PII-040 NOVEL METHODOLOGY FOR ESTIMATING THE TREATMENT EFFECT IN PRESENCE OF HIGHLY VARIABLE PLACEBO RESPONSE.
• PII-041 INVESTIGATION INTO THE INTERCHANGEABILITY OF GENERIC FORMULATIONS USING A RANDOM SELECTION OF MEDICINES AND IMMUNOSUPPRESSANTS.
• PII-042 A PHASE I STUDY TO DETERMINE THE SINGLE DOSE SAFETY AND PHARMACOKINETICS OF SYM-1219 (SECNIDAZOLE) IN HEALTHY FEMALE VOLUNTEERS.
• PII-043 EFFECT OF FOOD ON THE PHARMACOKINETICS OF ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITOR CERITINIB IN HEALTHY SUBJECTS.
• PII-044 DRUG INTERACTION POTENTIAL OF EMTRICITABINE (F; FTC)/TENOFOVIR (TFV) ALAFENAMIDE (TAF) (F/TAF) FIXED DOSE COMBINATION AND COBICISTAT (COBI)-BOOSTED DARUNAVIR (DRV).
• PII-045 SAFETY, TOLERABILITY AND PHARMACOKINETIC CHARACTERISITCS OF VVZ-149 INJECTION IN HEALTHY SUBJECTS.
• PII-046 NO DOSE ADJUSTMENT IS NEEDED WHEN COADMINISTERING DULAGLUTIDE WITH A COMBINATION ORAL CONTRACEPTIVE.
• PII-047 SITE OF INJECTION DOES NOT AFFECT DULAGLUTIDE PHARMACOKINETICS.
• PII-048 POPULATION PHARMACODYNAMIC MODELING OF LANREOTIDE AUTOGEL IN JAPANESE ACROMEGALIC PATIENTS.
• PII-049 A TARGET MEDIATED DRUG DISPOSITION (TMDD) DOSE OPTIMIZATION OF RG7116, A HER3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS EXPRESSING HER3.
• PII-050 EFFECTS OF ETHANOL ON ASPIRIN HYDROLYSIS BY CARBOXYLESTERASE-2 IN HUMANS.
• PII-051 APPLICATION OF PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING TO BOSUTINIB PHARMACOKINETICS: PREDICTION OF DRUG-DRUG INTERACTIONS AS CYP3A SUBSTRATE.
• PII-052 APPLICATION OF PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING TO BOSUTINIB PHARMACOKINETICS: PREDICTION OF DRUG-DISEASE INTERACTION IN ORGAN DYSFUNCTION PATIENTS.
• PII-053 PHARMACOKINETICS AND TOLERABILITY OF IDP-73152 MESYLATE AFTER A SINGLE ORAL ADMINISTRATION UNDER FASTING AND FED CONDITIONS IN HEALTHY VOLUNTEERS.
• PII-054 A MULTIPLE-DOSE STUDY OF BLOCKADE OF OPIOID SUBJECTIVE EFFECTS BY SUBCUTANEOUS INJECTIONS OF DEPOT BUPRENORPHINE IN SUBJECTS WITH OPIOID USE DISORDER.
• PII-055 INFORMATIVE DROPOUT MODELING AND EXPOSURE-RESPONSE ANALYSIS FOR MAVRILIMUMAB PHASE IIB STUDY IN PATIENTS WITH RHEUMATOID ARTHRITIS.
• PII-056 MODELING AND SIMULATION-GUIDED RATIONAL DRUG DISCOVERY AND DEVELOPMENT: A CASE STUDY OF MAVRILIMUMAB.
• PII-057 ASSESSING SYNERGY OF DRUG AGONISTS USING A SURFACE RESPONSE ANALYSIS IN R.
• PII-058 EFFECT OF NEOMYCIN (N) ON THE PHARMACOKINETICS (PK) OF REGORAFENIB (REG).
• PII-059 POPULATION PHARMACOKINETIC ANALYSIS OF SUMATRIPTAN IN HEALTHY KOREAN MALE SUBJECTS.
• PII-060 EVALUATION OF THE TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ORALLY ADMINISTERED DWP05195, A NEW TRPV1 ANTAGONIST IN HEALTHY ADULT MALE VOLUNTEERS.
• PII-061 POPULATION PHARMACOKINETICS OF CIPROFLOXACIN AND DOSING RECOMMENDATION IN NEONATES AND INFANTS LESS THAN 3 MONTHS OF AGE.
• PII-062 DRUG-DRUG INTERACTIONS OF OMEPRAZOLE WITH THE HCV DIRECT ACTING ANTIVIRAL (DAA) COMBINATION OF ABT-450/R, OMBITASVIR AND DASABUVIR.
• PII-063 CONCENTRATION-QTc MODELING IN FIRST-IN-HUMAN STUDY TO ASSESS THE EFFECT OF THE INVESTIGATIONAL DRUG GS-4997 ON CARDIAC REPOLARIZATION.
• PII-064 CLINICAL PHARMACOKINETICS STUDIES AIMED AT EFFECTIVELY AND EFFICIENTLY MONITORING THERAPEUTIC DRUG MONITORING METHOD OF MYCOPHENOLIC ACID IN RENAL TRANSPLANT RECIPIENTS.
• PII-065 PHARMACOMETRICS ENABLED RATIONAL DETERMINATION OF OPTIMAL DOSING REGIMEN FOR BENRALIZUMAB PIVOTAL STUDIES IN ADULTS AND ADOLESCENTS WITH ASTHMA.
• PII-066 THE PAN-PHOSPHOINOSITIDE-3 KINASE INHIBITOR PICTILISIB (GDC-0941), AN <i>IN VITRO</i> CYP2C8 INHIBITOR, DOES NOT IMPACT THE PHARMACOKINETICS OF PACLITAXEL, A CYP2C8 SUBSTRATE.
• PII-067 BIOEQUIVALENCE OF ROSUVASTATIN/EZETIMIBE COMBINATION TABLETS AND CO-ADMINISTRATION OF ROSUVASTATIN AND EZETIMIBE IN HEALTHY KOREAN SUBJECTS.
• PII-068 POPULATION PHARMACOKINETIC-PHARMACODYNAMIC (PKPD) MODELING OF AMG 747, A GLYCINE TRANSPORTER TYPE 1 (GLYT 1) INHIBITOR, IN HEALTHY SUBJECTS.
• PII-069 CLINICAL PHARMACOLOGY STUDY OF TELAPREVIR IN HEALTHY KOREAN VOLUNTEERS AFTER SINGLE AND MULTIPLE ORAL ADMINISTRATIONS.
• PII-070 BIOEQUIVALENCE AND PHARMACOKINETIC EVALUATION OF TWO FORMULATIONS OF ULTRACET® ER TABLET.
• PII-071 APPLICATION OF PBPK AND BAYESIAN MODELING FOR PREDICTION OF THE LIKELIHOOD OF INDIVIDUAL PATIENTS EXPERIENCING SERIOUS ADVERSE REACTIONS TO A STANDARD DOSE OF EFAVIRENZ.
• PII-072 SERUM HEMOGLOBIN IS A PREDICTOR OF TACROLIMUS WHOLE BLOOD CONCENTRATION IN HEMATOPOEITIC STEM CELL TRANSPLANT PATIENTS.
• PII-073 ASSESSMENT OF PHARMACOKINETIC INTERACTION BETWEEN THE PI3K INHIBITOR TASELISIB (GDC-0032) AND A STRONG CYP3A4 INDUCER OR INHIBITOR.
• PII-074 PHARMACOKINETICS (PK) OF SUBCUTANEOUS (SC) AZACITIDINE (AZA) IN CHINESE SUBJECTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) FROM A PHASE II, OPEN-LABEL STUDY.
• PII-075 ASSESSMENT OF ABSOLUTE BIOAVAILABILITY AND MASS BALANCE OF THE PI3K INHIBITOR TASELISIB (GDC-0032) IN HEALTHY SUBJECTS.
• PII-076 POPULATION PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) MODELING FOR AN ANTISENSE OLIGONUCLEOTIDE (ISIS-FXIRx), TARGETING FACTOR XI, IN HEALTHY SUBJECTS.
• PII-077 PHARMACOKINETIC, PHARMACODYNAMIC AND TOLERBILITY PROFILES OF CKD-11101, A BIOSIMILAR TO NESP^®, AFTER A SINGLE SUBCUTANEOUS ADMINISTRATION IN HEALTHY VOLUNTEERS.
• PII-078 POPULATION PHARMACOKINETICS OF KRN23, A HUMAN ANTI-FGF23 ANTIBODY DEVELOPED FOR THE TREATMENT OF ADULTS WITH X-LINKED HYPOPHOSPHATEMIA.
• PII-079 IMMUNOGENICITY AND TOLERABILITY OF NOVEL HUMAN PAPILLOMAVIRUS-16/18 VACCINE IN HEALTHY MALE VOLUNTEERS.
• PII-080 PHARMACOKINETIC, PHARMACODYNAMIC AND TOLERBILITY PROFILES OF CKD-11101, A BIOSIMILAR TO NESP®, AFTER A SINGLE INTRAVENOUS ADMINISTRATION IN HEALTHY VOLUNTEERS.
• PII-081 EFFECT OF ACID REDUCING AGENTS ON THE PHARMACOKINETICS OF IDELALISIB, A NOVEL PI3Kδ INHIBITOR, IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES.
• PII-082 PHARMACOKINETICS, PHARMACODYNAMICS, IMMUNOGENICITY, AND SAFETY OF BMS-938790 IN HEALTHY SUBJECTS.
• PII-083 PHARMACOKINETIC COMPARISON OF COMPOUND K AFTER ORAL ADMINISTRATION OF FERMENTED RED GINSENG EXTRACTS, RED GINSENG EXTRACTS AND GINSENG EXTRACTS IN HEALTHY SUBJECTS.
• PII-084 EFFECT OF INTRINSIC AND EXTRINSIC FACTORS ON PHARMACOKINETICS OF IDELALISIB, A NOVEL PI3Kδ INHIBITOR, IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES.
• PII-085 PHARMACOKINETICS OF BRENTUXIMAB VEDOTIN IN HODGKIN LYMPHOMA PATIENTS AGED 60 AND ABOVE.
• PII-086 POPULATION PHARMACOKINETICS OF TD-9855, A NOREPINEPHRINE AND SEROTONIN REUPTAKE INHIBITOR (NSRI), IN HEALTHY SUBJECTS AND PATIENTS WITH ADULT ADHD OR FIBROMYALGIA.
• PII-087 POPULATION PHARMACOKINETICS OF BELIMUMAB IN HEALTHY AMERICAN AND JAPANESE SUBJECTS FOLLOWING SUBCUTANEOUS ADMINISTRATION.
• PII-088 EFFECT OF RENAL AND HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF CABOZANTINIB (CABO).
• PII-089 PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) ANALYSES OF ARGININE VASOPRESSIN TYPE-1B (V1B) RECEPTOR ANTAGONIST EFFECT ON CORTISOL.
• PII-090 POTENTIAL PRASUGREL DRUG INTERACTIONS BASED ON INHIBITION OF CARBOXYLESTERASE-2.
• PII-091 POPULATION PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSIS OF ECULIZUMAB TO SUPPORT PHASE III DOSING REGIMEN IN PATIENTS WITH REFRACTORY GENERALIZED MYASTHENIA GRAVIS.
• PII-092 A PHASE I, OPEN-LABEL STUDY TO DETERMINE THE EFFECT OF SYM-1219 ON THE PHARMACOKINETICS OF ETHINYL ESTRADIOL (EE2) AND NORETHINDRONE (NET) IN HEALTHY FEMALE VOLUNTEERS.
• PII-093 ATAZANAVIR ABSORPTION IN HEALTHY VOLUNTEERS WITH PHARMACOLOGICALLY-INDUCED HYPOCHLORHYDRIA USING BETAINE HCL.
• PII-094 A PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL FOR PREDICTION OF PLASMA AND LUNG CONCENTRATIONS AFTER ADMINISTRATION OF CEFTAZIDIME.
• PII-095 POPULATION PHARMACOKINETICS AND EXPOSURE-RESPONSE ASSESSMENT OF ANTI-CD79B ANTIBODY DRUG CONJUGATE IN PATIENTS: INTERIM ANALYSIS RESULTS.
• PII-096 PHARMACOKINETICS AND SAFETY OF SINGLE ASCENDING DOSES, FOOD EFFECT AND KETOCONAZOLE (KTZ) INTERACTION OF ARGININE VASOPRESSIN TYPE-1B (V1B) RECEPTOR ANTAGONIST ABT-436.
• PII-097 PHARMACOKINETIC/PHARMACODYNAMIC MODELING OF HUMAN ANTI-FGF23 ANTIBODY (KRN23) AND SERUM PHOSPHORUS IN ADULTS WITH X-LINKED HYPOPHOSPHATEMIA.
• PII-098 PHARMACOKINETICS (PK) AND SAFETY OF ARGININE VASOPRESSIN TYPE-1B (V1B) RECEPTOR ANTAGONIST ABT-436 IN HEALTHY VOLUNTEERS FOLLOWING MULTIPLE DOSES.
• PII-099 A CONCENTRATION-QTC ANALYSIS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER RECEIVING CRIZOTINIB: ACCOUNTING FOR BIAS IN CORRECTION METHODS.
• PII-100 OPPOSITE EFFECTS OF ST. JOHN’S WORT AND RIFAMPIN ON GLUCOSE METABOLISM IN HEALTHY VOLUNTEERS.
• PII-101 AZITHROMYCIN IS NOT ASSOCIATED WITH QT PROLONGATION IN HOSPITALIZED PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA.
• PII-102 THE CATASTROPHIC FIRST-IN-HUMAN TGN1412 TRIAL; A SYSTEMATIC REVIEW OF PUBLICATION PATTERNS AND LESSONS LEARNED SINCE THE 2006 INCIDENT.
• PII-103 EVALUATION OF THE QTC PROLONGATION POTENTIAL OF TWO NEUROPSYCHIATRIC DRUGS QUETIAPINE AND ESCITALOPRAM IN HEALTHY VOLUNTEERS.
• PII-104 ASSOCIATION OF MEGALIN GENETIC POLYMORPHISMS WITH ACUTE KIDNEY INJURY (AKI) IN AMINOGLYCOSIDE (AG)-TREATED NEWBORNS.
• PII-105 THE PHARMACOGENETICS OF CODEINE PAIN RELIEF IN THE POSTPARTUM PERIOD.
• PII-106 STEADY-STATE PHARMACOKINETICS OF GSK1278863 AND METABOLITES IN SUBJECTS WITH NORMAL AND IMPAIRED RENAL FUNCTION.
• PII-107 ANALYSIS OF THE EFFECT OF VARIOUS DEGREES OF RENAL IMPAIRMENT ON THE PHARMACOKINETICS OF NONRENALLY ELIMINATED DRUGS.
• PII-108 AGE-DEPENDENT CHANGES IN CYP3A METABOLIC CAPACITY DETERMINE SIROLIMUS CLEARANCE IN PEDIATRIC PATIENTS.
• PII-109 THE EFFECT OF HEPATIC IMPAIRMENT (HI) OR HCV INFECTION ON THE PHARMACOKINETICS (PK) OF BUPRENORPHINE AND NALOXONE.
• PII-110 PHARMACOKINETICS OF ELAGOLIX, A NOVEL ORAL GONADOTROPIN-RELEASING HORMONE (GnRH) ANTAGONIST ADMINISTERED TO FEMALE SUBJECTS WITH HEPATIC IMPAIRMENT.
• PII-111 PHARMACOKINETICS OF ELAGOLIX, A NOVEL ORAL GONADOTROPIN-RELEASING HORMONE (GnRH) ANTAGONIST, ADMINISTERED TO FEMALE SUBJECTS WITH RENAL IMPAIRMENT.
• PII-112 PHARMACOKINETICS OF SINGLE DOSE ESCITALOPRAM IN THE HEALTHY ELDERLY COMPARED WITH THE YOUNG.
• PII-113 PHARMACOKINETICS (PK) OF TWO 6-MERCAPTOPURINE (6-MP) LIQUID FORMULATIONS IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL).
• PII-114 ELUCIDATION OF THE MECHANISM OF THERAPEUTIC PROTEIN-DRUG INTERACTION (TPDI) BETWEEN METHOTREXATE (MTX) AND AN ANTI-TNFα MONOCLONAL ANTIBODY (MAB), GOLIMUMAB.
• PII-115 IMMUNOGENICITY OF NIVOLUMAB AND ITS IMPACT ON PHARMACOKINETICS (PK) AND SAFETY IN SUBJECTS WITH METASTATIC SOLID TUMORS.
• PII-116 PHARMACOKINETICS AND PHARMACODYNAMICS OF BENRALIZUMAB IN SUBJECTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE.
• PII-117 ABSENCE OF QT PROLONGATION (QTP) EFFECT BY NIVOLUMAB (NIVO) OR IPILIMUMAB (IPI) IN SUBJECTS WITH SOLID TUMORS.
• PII-118 ASSESSMENT OF DRUG INTERACTION POTENTIAL BY NIVOLUMAB USING CYTOKINE MODULATION DATA.
• PII-119 ASSESSMENT OF CLINICAL RESPONSE IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) BETWEEN PF-05280586, A PROPOSED BIOSIMILAR TO RITUXIMAB AND TWO RITUXIMAB PRODUCTS.